$ESPR
Esperion Therapeutics, Inc. Stock $espr

$espr Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000104746914002320 Filed on March 13, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2013 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.500M	$2.400M	$1.900M
YoY Change	92.31%	380.0%	280.0%
% of Gross Profit
Research & Development	$5.400M	$7.339M	$3.483M
YoY Change	158.0%	343.61%	41.78%
% of Gross Profit
Depreciation & Amortization	$12.00K	$10.00K	$10.00K
YoY Change	-62.5%	-66.67%	-75.0%
% of Gross Profit
Operating Expenses	$7.890M	$9.736M	$5.407M
YoY Change	135.94%	350.73%	80.82%
Operating Profit	-$7.890M	-$9.736M	-$5.407M
YoY Change	135.94%	350.73%	80.82%
Interest Expense	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$16.00K	$46.57K	$168.4K
YoY Change	-164.0%	-154.15%	41892.27%
Pretax Income	-$7.900M	-$9.700M	-$5.200M
YoY Change	88.1%	246.43%	52.94%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.874M	-$9.689M	-$5.238M
YoY Change	85.75%	249.12%	56.31%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$513.0K	-$629.9K	-$339.9K
COMMON SHARES
Basic Shares Outstanding	15.39M shares	15.36M shares	15.36M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q4	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$56.70M	$60.10M	$71.90M
YoY Change	1353.85%
Cash & Equivalents	$48.64M	$56.54M	$71.90M
Short-Term Investments	$8.100M	$3.500M
Other Short-Term Assets	$1.600M	$600.0K	$1.000M
YoY Change	33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$58.28M	$60.62M	$72.96M
YoY Change	1042.73%	749.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$360.0K	$81.00K	$78.75K
YoY Change	260.0%	-32.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$11.50M	$17.50M	$13.50M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$11.94M	$17.67M	$13.61M
YoY Change	5872.0%	10055.43%
TOTAL ASSETS
Total Short-Term Assets	$58.28M	$60.62M	$72.96M
Total Long-Term Assets	$11.94M	$17.67M	$13.61M
Total Assets	$70.22M	$78.29M	$86.58M
YoY Change	1224.96%	970.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.098M	$2.232M	$1.945M
YoY Change	133.11%	368.63%
Accrued Expenses	$1.100M	$2.000M	$1.400M
YoY Change	-26.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.188M	$4.203M	$3.343M
YoY Change	18.07%	-75.53%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.188M	$4.203M	$3.343M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.188M	$4.203M	$3.343M
YoY Change	-68.75%	-82.99%
SHAREHOLDERS EQUITY
Retained Earnings		-$68.06M
YoY Change
Common Stock	$15.00K	$15.00K	$15.36K
YoY Change		4235.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$67.04M	$74.09M	$83.23M
YoY Change
Total Liabilities & Shareholders Equity	$70.22M	$78.29M	$86.58M
YoY Change	1224.96%	970.7%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2013 Q3
OPERATING ACTIVITIES
Net Income	-$7.874M	-$9.689M	-$5.238M
YoY Change	85.75%	249.12%	56.31%
Depreciation, Depletion And Amortization	$12.00K	$10.00K	$10.00K
YoY Change	-62.5%	-66.67%	-75.0%
Cash From Operating Activities	-$9.100M	-$7.530M	-$4.770M
YoY Change	246.01%	217.72%	63.92%
INVESTING ACTIVITIES
Capital Expenditures	$273.0K	-$10.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$1.430M	-$7.640M	-$13.39M
YoY Change			-134000.0%
Cash From Investing Activities	$1.150M	-$7.650M	-$13.39M
YoY Change			-134000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	50.00K	-180.0K	73.44M
YoY Change		-103.15%	1726.87%
NET CHANGE
Cash From Operating Activities	-9.100M	-7.530M	-4.770M
Cash From Investing Activities	1.150M	-7.650M	-13.39M
Cash From Financing Activities	50.00K	-180.0K	73.44M
Net Change In Cash	-7.900M	-15.36M	55.28M
YoY Change	200.38%	-559.88%	4835.71%
FREE CASH FLOW
Cash From Operating Activities	-$9.100M	-$7.530M	-$4.770M
Capital Expenditures	$273.0K	-$10.00K	$0.00
Free Cash Flow	-$9.373M	-$7.520M	-$4.770M
YoY Change	256.39%	217.3%	63.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6511521	USD
CY2012Q4	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	367216	USD
CY2012Q4	espr	Other Prepaid Expense And Assets Current OtherPrepaidExpenseAndAssetsCurrent	259669	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	7138406	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	120210	USD
CY2012Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	53825	USD
CY2012Q4	us-gaap	Assets Assets	7312441	USD
CY2012Q4	espr	Short Term Borrowings Related Party Net ShortTermBorrowingsRelatedPartyNet	15241007	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	738192	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	476277	USD
CY2012Q4	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	242171	USD
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	265323	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	210329	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17173299	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7528845	USD
CY2012Q4	us-gaap	Liabilities Liabilities	24702144	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	346	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4202491	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	15357	USD
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	609976	USD
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	41975025	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7312441	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	346478	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	346478	shares
CY2013Q4	us-gaap	Assets Current AssetsCurrent	60619649	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3034	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78293860	USD
CY2013Q4	us-gaap	Liabilities Liabilities	4202491	USD
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15340710	shares
CY2013	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	16014205	USD
CY2012	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7998128	USD
CY2011	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7807702	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2205632	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2356669	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	85612	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	22758698	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	10203760	USD
	us-gaap	Operating Expenses OperatingExpenses	61707867	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-22758698	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-10203760	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-10164371	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-61463388	USD
CY2012	us-gaap	Interest Expense InterestExpense	1486696	USD
CY2011	us-gaap	Interest Expense InterestExpense	577157	USD
CY2012	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-32367	USD
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-75813	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-11741736	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-10817341	USD
	us-gaap	Net Income Loss NetIncomeLoss	-68063158	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.31
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-36.31
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-36.22
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-3034	USD
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7885921	shares
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	298689	shares
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-46758	USD
CY2013	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-3034	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11741736	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68066192	USD
CY2011	us-gaap	Depreciation Depreciation	178471	USD
CY2012	us-gaap	Depreciation Depreciation	139433	USD
CY2012	espr	Amortization Of Debt Discount Premium And Beneficial Conversion AmortizationOfDebtDiscountPremiumAndBeneficialConversion	116988	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	78451	USD
CY2012	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-86887	USD
CY2011	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-108308	USD
CY2012	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	2549	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	429720	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26091167	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10817341	USD
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	15378	USD
CY2013	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-46758	USD
CY2012	us-gaap	Paid In Kind Interest PaidInKindInterest	1369709	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	79861	USD
CY2011	us-gaap	Paid In Kind Interest PaidInKindInterest	577065	USD
CY2011	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	4400	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-168277	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-214903	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	619238	USD
CY2012	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-195548	USD
CY2011	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	14406	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9068725	USD
CY2013	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	24676822	USD
CY2011	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	500350	USD
CY2013	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	201265	USD
CY2012	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	5100	USD
CY2011	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	42312	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6783	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33635	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	72193831	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-21002139	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1683	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	509027	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-18021689	USD
CY2013	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	72193831	USD
	espr	Proceeds From Issuance Of Preferred Stock And Preference Stock Net Of Issuance Costs ProceedsFromIssuanceOfPreferredStockAndPreferenceStockNetOfIssuanceCosts	40799235	USD
CY2013	espr	Proceeds From Issuance Of Preferred Stock And Preference Stock Net Of Issuance Costs ProceedsFromIssuanceOfPreferredStockAndPreferenceStockNetOfIssuanceCosts	16824235	USD
CY2011	espr	Proceeds From Issuance Of Preferred Stock And Preference Stock Net Of Issuance Costs ProceedsFromIssuanceOfPreferredStockAndPreferenceStockNetOfIssuanceCosts	6700000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	123274	USD
CY2012	espr	Proceeds From Issuance Of Warrants Fair Value Estimate ProceedsFromIssuanceOfWarrantsFairValueEstimate	297690	USD
CY2012	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	15412010	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15750687	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6715886	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	128886863	USD
CY2013	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	50025840	USD
CY2012	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	4940437	USD
CY2011	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-1843812	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	56537361	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	Esperion Therapeutics, Inc.
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001434868
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15394226	shares
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014Q1	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	396414	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14607413	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15357413	shares
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Concentration of Credit Risk</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to concentrations of credit risk. The Company has established guidelines for investment of its excess cash and believes the guidelines maintain safety and liquidity through diversification of counterparties and maturities.</font></p> </div>
CY2013	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
CY2013	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	USD
CY2008	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	85612	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	344604	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	335000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1631004	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	100868	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	100868	USD
CY2013Q3	dei	Entity Public Float EntityPublicFloat	204600000	USD
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	768607	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1286046	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	687799	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1165836	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	209961	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	136907	USD
CY2013Q4	espr	Accrued Franchise And Property Taxes Current AccruedFranchiseAndPropertyTaxesCurrent	94600	USD
CY2012Q4	espr	Accrued Franchise And Property Taxes Current AccruedFranchiseAndPropertyTaxesCurrent	12697	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	41203	USD
CY2012Q4	espr	Investments And Cash Fair Value Disclosure InvestmentsAndCashFairValueDisclosure	6357542	USD
CY2012Q4	espr	Investments And Cash Amortized Cost InvestmentsAndCashAmortizedCost	6357542	USD
CY2013Q4	espr	Investments And Cash Fair Value Disclosure InvestmentsAndCashFairValueDisclosure	26419238	USD
CY2013Q4	espr	Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments	4392	USD
CY2013Q4	espr	Available For Sale Debt Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments	7426	USD
CY2013Q4	espr	Investments And Cash Amortized Cost InvestmentsAndCashAmortizedCost	26422272	USD
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	55740	USD
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	17537663	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	USD
CY2012	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	USD
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Revenue From Grants RevenueFromGrants	244479	USD
CY2013	espr	Fair Value Measurement Liability Transfers Between Levels FairValueMeasurementLiabilityTransfersBetweenLevels	0	USD
CY2012	espr	Fair Value Measurement Liability Transfers Between Levels FairValueMeasurementLiabilityTransfersBetweenLevels	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	2500000	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	211500	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1401101	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1251749	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	12212	shares
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	49936	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.43
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.59
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.62
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.03
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.47
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M12D
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	141389	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7755321	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1334221	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	594176	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.49
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.81
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y11M1D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y1M28D
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	7505458	USD
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6572563	USD
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7346725	USD
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y6M
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1431	pure
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-50626	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7351778	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1695494	shares
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2231890	USD
CY2013	us-gaap	Depreciation Depreciation	70551	USD
	us-gaap	Depreciation Depreciation	1447722	USD
CY2013Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	74208	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	667164	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	60725	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1087136	USD
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	USD
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	USD
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	184097	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1571084	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0145	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0085	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0158	pure
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M4D
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M4D
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.74	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.80	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.14
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.33
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.94
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1226988	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	79861	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1484096	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22804000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14351000	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.007	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.049	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.004	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.032	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.291	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.338	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22485000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14207000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	319000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	144000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22804000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14351000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	200	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3750	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	98796	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19415948	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15886	USD
CY2011	us-gaap	Stock Issued During Period Value Issued For Noncash Considerations StockIssuedDuringPeriodValueIssuedForNoncashConsiderations	4400	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	78451	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	40988	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	287990	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	79861	USD
CY2013	espr	Stock Issued During Period Value Exercise Of Stock Options And Vesting Of Restricted Stock StockIssuedDuringPeriodValueExerciseOfStockOptionsAndVestingOfRestrictedStock	21193	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	65225165	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	72193831	USD
CY2013	espr	Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liabilities To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilitiesToEquity	2852188	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27874	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1226988	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3034	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-19313202	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-30031806	USD
CY2010Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3414896	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56537361	USD
CY2013Q4	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	195652	USD
CY2013Q4	espr	Other Prepaid Expense And Assets Current OtherPrepaidExpenseAndAssetsCurrent	361513	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80808	USD
CY2013Q4	us-gaap	Assets Assets	78293860	USD
CY2013Q4	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	883465	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	142142204	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	68063158	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	74091369	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	43428066	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6744493	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18194189	USD
CY2013	us-gaap	Interest Expense InterestExpense	936580	USD
	us-gaap	Interest Expense InterestExpense	4320696	USD
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2586865	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2554498	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	194010	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	275424	USD
CY2013	espr	Amortization Of Debt Discount Premium And Beneficial Conversion AmortizationOfDebtDiscountPremiumAndBeneficialConversion	458993	USD
	espr	Amortization Of Debt Discount Premium And Beneficial Conversion AmortizationOfDebtDiscountPremiumAndBeneficialConversion	575981	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	18533	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	33911	USD
CY2013	us-gaap	Paid In Kind Interest PaidInKindInterest	459055	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	3726092	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1226988	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1484096	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	4400	USD
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-27000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-322701	USD
CY2013	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	147805	USD
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	166264	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-28489	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	508281	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1755613	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2231890	USD
CY2013	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1443732	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1896229	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18113361	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-54327813	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	56245988	USD
CY2013	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	3504791	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	35020141	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	952464	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31373	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	298932	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	40987	USD
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15886	USD
	espr	Proceeds From Issuance Of Warrants Fair Value Estimate ProceedsFromIssuanceOfWarrantsFairValueEstimate	297690	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	15412010	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	89141340	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	3525123	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Use of Estimates</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures. Actual results could differ from those estimates.</font></p> <p style="FONT-FAMILY: times;"><font size="2">        Prior to the completion of the IPO on July 1, 2013, the Company utilized significant estimates and assumptions in determining the fair value of its Common Stock. The Company utilized valuation methodologies in accordance with the framework of the 2004 American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its Common Stock. Each valuation methodology includes estimates and assumptions that require the Company's judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the prices at which the Company sold shares of its Preferred Stock, the superior rights and preferences of securities senior to its Common Stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of Common Stock at each valuation date.</font></p> </div>
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2012Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	5000000	USD
CY2012Q4	espr	Debt Instrument Accumulated Paid In Kind Interest DebtInstrumentAccumulatedPaidInKindInterest	2528845	USD
CY2012Q4	us-gaap	Borrowed Funds BorrowedFunds	22769852	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	323000	USD
CY2008Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0250	pure
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.80	pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.12
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	78451	USD
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0	USD
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10386000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	4271847	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	5406823	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	9736016	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3344012	USD
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	346478	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	349170	shares
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.001	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.316	pure
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2013Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2092593	USD
CY2013Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3100422	USD
CY2013Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3482673	USD
CY2013Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7338517	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1251419	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1171425	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1924150	USD
CY2013Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2397499	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	3344012	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4271847	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5406823	USD
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9736016	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	828223	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	108357	USD
CY2013Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	41958	USD
CY2013Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2544907	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-24984	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4035	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	168389	USD
CY2013Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	46570	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-4239177	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-6921076	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-5238434	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-9689446	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-12.24
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-19.82
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15253704	shares
CY2013Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15340713	shares
CY2012Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1557211	USD
CY2012Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2330223	USD
CY2012Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2456412	USD
CY2012Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1654282	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	632372	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	533658	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	533837	USD
CY2012Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	505765	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	2189583	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	2863881	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	2990249	USD
CY2012Q4	us-gaap	Operating Expenses OperatingExpenses	2160047	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2189583	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2863881	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2990249	USD
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2160047	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	260428	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	303167	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	361426	USD
CY2012Q4	us-gaap	Interest Expense InterestExpense	561675	USD
CY2012Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-32367	USD
CY2012Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1059	USD
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	894	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	401	USD
CY2012Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-86001	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-2448952	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-3166154	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-3351274	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-2775356	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.96
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.94
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-10.31
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.12
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	307742	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	318654	shares
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	325023	shares
CY2012Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	341935	shares
CY2013	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Reclassifications</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">        Certain prior period information has been reclassified to be comparable to the current year presentation. These items had no impact on the amounts of previously reported net loss or total shareholder's equity (deficit).</font></p> </div>
CY2011	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2013Q4	espr	Deferred Tax Assets Operating Loss Carryforwards Related To Stock Awards DeferredTaxAssetsOperatingLossCarryforwardsRelatedToStockAwards	191000	USD
CY2008Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	44025145	shares
CY2008Q2	espr	Number Of New Series Preferred Stock Authorized NumberOfNewSeriesPreferredStockAuthorized	2	item
CY2010Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45025145	shares
CY2011Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	56519253	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	58220375	shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75220375	shares

Files In Submission

Name	View Source	Status
0001047469-14-002320-index-headers.html	Edgar Link	pending
0001047469-14-002320-index.html	Edgar Link	pending
0001047469-14-002320.txt	Edgar Link	pending
0001047469-14-002320-xbrl.zip	Edgar Link	pending
a2218757z10-k.htm	Edgar Link	pending
a2218757zex-23_1.htm	Edgar Link	pending
a2218757zex-31_1.htm	Edgar Link	pending
a2218757zex-32_1.htm	Edgar Link	pending
espr-20131231.xml	Edgar Link	completed
espr-20131231.xsd	Edgar Link	pending
espr-20131231_cal.xml	Edgar Link	unprocessable
espr-20131231_def.xml	Edgar Link	unprocessable
espr-20131231_lab.xml	Edgar Link	unprocessable
espr-20131231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g697431.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESPR
Esperion Therapeutics, Inc. Stock $espr

2014 Q1 Form 10-K Financial Statement

#000104746914002320 Filed on March 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR Esperion Therapeutics, Inc. Stock $espr

2014 Q1 Form 10-K Financial Statement

#000104746914002320 Filed on March 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR
Esperion Therapeutics, Inc. Stock $espr